Concerto's clinical trial, ENS-002 for Atopic Dermatitis in Adults, is now recruiting.More information
The Latest
News & Press
Dermatology Times • 11 20 2024
Concerto Biosciences Doses First Participant in Phase 1 Trial of ENS-002, a Microbiome-Based Therapy for Atopic Dermatitis
MSN • 11 20 2024
Concerto doses first subject in Phase I trial of ENS-002 for atopic dermatitis
From Concerto • 11 19 2024
Concerto Biosciences Announces First Participant Dosed with Live Biotherapeutic ENS-002 in Phase 1 Trial for Atopic Dermatitis
Bio.News • 7 11 2024
NIH Innovation Zone 2024: Concerto Biosciences illuminates collaboration of microbes
From Concerto • 6 26 2024
Concerto Biosciences Receives FDA Investigational New Drug Clearance for Live Biotherapeutic Product to Treat Atopic Dermatitis
Dermatology Times • 6 26 2024
FDA Grants Investigational New Drug Clearance for Ensemble No.2 for Phase 1 Atopic Dermatitis Trial
Microbe Musings • 4 29 2024
Jared Kehe: Unlock the Microbial Sound of Music
Homeworld Collective • 12 19 2023
Communion: The Future of Biotech, by CSO Jared Kehe
Saturday Startup Stories • 11 26 2023
Upgrading Humanity's Microbes
From Concerto • 7 26 2023
Concerto Biosciences Expands Executive Leadership Team To Support Product Development And Business Partnership Initiatives
Microbiome Times • 6 30 2023
Concerto Biosciences Announces Discovery Initiative to Combat Recurrent Vaginal Yeast Infections
From Concerto • 6 20 2023
Concerto Biosciences Announces Discovery Initiative to Combat Recurrent Vaginal Yeast Infections with Novel Live Microbial Product
From Concerto • 5 8 2023
Concerto Biosciences Co-Founder and CEO Cheri Ackerman Selected as an Ernst & Young Entrepreneur Of The Year® 2023 New England Finalist
Global Corporate Venturing • 4 21 2023
AI and Genome Sequencing Open Up New Microbiome Treatments
From Concerto • 2 6 2023
Concerto Biosciences Announces Strategic Business Development Hire
MIT Alumni • 2 3 2023
Overturning a Century of Misunderstanding Microbes
Endpoints • 11 4 2022
'Rulebook of Microbial Ecology': Pianists Launch Concerto to Treat Eczema, Protect Crops and Get Rid of BO
From Concerto • 11 2 2022
Concerto Biosciences Raises $23 Million in Series A to Advance Product Development, Expand Pipeline
Mathworks • 12 13 2021
Startup of the Month: Concerto Biosciences – Discovering the microbial orchestra around us
Chemical and Engineering News • 11 11 2021
Many bacteria lend other species a helping hand
BIOS Community • 9 30 2021
Founder Spotlight: Cheri Ackerman
Petri • 6 3 2021
Concerto CEO receives Emerging Women Founder Award
MIT News • 1 5 2021
Turning microbiome research into a force for health
AAAS EurekAlert! • 11 19 2020
Hertz Foundation Entrepreneurship Award to support microbial innovation
Activate Global • 6 1 2020
Concerto CEO and CSO awarded Activate Fellowships
About Us
Reinventing humanity’s relationship with microbes.
In partnership with a diverse array of biotech and biopharma companies, Concerto aims to unleash a new era of microbial research and a treasure trove of microbe-based products.Harness microbial ecology with Concerto to develop new, transformative products.
Partner With UsMicrobes, like humans, are stronger together than they ever could be alone.
Visit Us
750 Main Street
Cambridge, MA 02139
© 2024 Concerto Biosciences, Inc. All rights reserved.